Genmab (GMAB)
(Real Time Quote from BATS)
$28.14 USD
+0.68 (2.48%)
Updated Apr 26, 2024 10:22 AM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Genmab A/S Sponsored ADR (GMAB) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$40.63 | $50.00 | $29.00 | 47.96% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Genmab A/S Sponsored ADR comes to $40.63. The forecasts range from a low of $29.00 to a high of $50.00. The average price target represents an increase of 47.96% from the last closing price of $27.46.
Analyst Price Targets (8 )
Broker Rating
Genmab A/S Sponsored ADR currently has an average brokerage recommendation (ABR) of 2.18 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 17 brokerage firms. The current ABR compares to an ABR of 2.26 a month ago based on 18 recommendations.
Of the 17 recommendations deriving the current ABR, nine are Strong Buy, representing 52.94% of all recommendations. A month ago, Strong Buy represented 50%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 9 | 8 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 6 | 6 | 6 | 6 | 7 |
Sell | 0 | 0 | 1 | 1 | 1 |
Strong Sell | 2 | 2 | 2 | 2 | 2 |
ABR | 2.18 | 2.18 | 2.26 | 2.26 | 2.37 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/26/2024 | Truist Securities | Asthika S Goonewardene | Strong Buy | Strong Buy |
3/6/2024 | H.C. Wainwright & Co. | Raghuram Selvaraju | Strong Buy | Strong Buy |
2/23/2024 | BMO Capital Markets | Etzer Darout | Hold | Strong Buy |
2/15/2024 | William Blair | Matt Phipps | Hold | Hold |
2/12/2024 | SVB Securities | Jonathan W Chang | Hold | Hold |
1/7/2024 | BTIG | Kaveri Pohlman | Strong Buy | Strong Buy |
11/8/2023 | Guggenheim Securities | Michael Schmidt | Not Available | Hold |
10/18/2023 | Exane BNP Paribas | Victor Floch | Not Available | Strong Sell |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.18 |
ABR (Last week) | 2.18 |
# of Recs in ABR | 17 |
Average Target Price | $40.63 |
LT Growth Rate | 13.10% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 75 of 252 |
Current Quarter EPS Est: | 0.16 |